Foghorn Therapeutics Inc.: quarterly results
Price
$2.07
November 13, 2026Market cap $122M
What Ploutos Investor adds for Foghorn Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Profit over the last twelve months is well above what the business itself earned, because it includes large gains outside the business, such as on investments or from selling a business. The P/E is lower than the business alone would give.
- Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.
Results, quarter by quarter
When the company put out each quarter's results (its 8-K, item 2.02), what they showed against the same quarter a year before, and how the stock moved on the first session after.
Next results
last Nov 9, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
The first session after results
±11.6%average move, either way
2 times upof the last 42 times down
Largest: +14.1% on Aug 6, 2026 (Q2 2026).
How the stock moved after each release
The close of the first session after the results against the close before them.
FHTX that sessionS&P 500 the same day
Every release
Revenue and diluted EPS of the quarter reported, with the change against the same quarter a year before.
- Q3 2026Stock, next session+9.1%
- Q2 2026Stock, next session+14.1%
- Q1 2026Stock, next session-10.3%
- Q4 2025Stock, next session-12.9%
| Quarter | Released | Revenue | EPS | Stock, next session | S&P 500 | Filing |
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 9, 2026before the close | $84M+924.7% | $0.80 | +9.1% | +2.3% | 8-K |
| Q2 2026 | Aug 6, 2026before the close | $16M+112.7% | -$0.10 | +14.1% | -0.2% | 8-K |
| Q1 2026 | May 7, 2026before the close | $3.3M-45.1% | -$0.29 | -10.3% | -0.4% | 8-K |
| Q4 2025 | Mar 11, 2026after the close | $9.2M+223.8% | -$0.34 | -12.9% | -1.5% | 8-K |
Every release
FHTX's results days and the share's move after each, from Q3 2020 to Q4 2025, 23 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 8 quarters.
Times are the SEC's acceptance of the 8-K, in New York time: before 16:00 the market traded on it that day, after it the next day. A move on a results day has other causes too, and says nothing about the next one.
The full analysis
What do Foghorn Therapeutics's filings show?
The results say what Foghorn Therapeutics reported. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.